Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acetaminophen + pseudoephedrine hydrochloride + chlorphenamine maleate
- Development stage
- Unknown
- Lead developer
- Northeast Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is an approved small molecule combination drug developed by Northeast Pharmaceutical Group for the treatment of influenza and common cold symptoms. The formulation comprises three active ingredients that work through complementary mechanisms: acetaminophen (paracetamol), pseudoephedrine hydrochloride, and chlorphenamine maleate (chlorpheniramine). Acetaminophen serves as an analgesic and antipyretic by inhibiting cyclooxygenase (COX) enzymes, thereby reducing pain and fever. Pseudoephedrine acts as an α-adrenergic receptor agonist, causing vasoconstriction in the nasal mucosa to relieve congestion. Chlorphenamine is a first-generation H1 receptor antagonist that blocks the effects of histamine to reduce sneezing, rhinorrhea, and other allergic-type symptoms. This combination is designed to provide comprehensive relief from multi-symptom respiratory infections.
- Brand names
- Coldrex
- Other names
- Paracetamol + Pseudoephedrine Hydrochloride + Chlorphenamine MaleateParacetamol/Pseudoephedrine/Chlorpheniramine combination
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ADRA1A (α1A)PGHS-1 (Prostaglandin G/H Synthase 1)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on acetaminophen + pseudoephedrine hydrochloride + chlorphenamine maleate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acetaminophen + pseudoephedrine hydrochloride + chlorphenamine maleate.